Eradivir, PNAS publication of EV25 research (IMAGE)
Caption
An Eradivir employee conducts research on the company’s EV25 influenza therapeutic. Research published in the Proceedings of the National Academy of Sciences shows EV25 acts faster and has a broader window of efficacy than the current standard of care for influenza.
Credit
(Eradivir photo/Gregory Eakins)
Usage Restrictions
None
License
Original content